Clinical Trials Logo

Chronic Stable Angina clinical trials

View clinical trials related to Chronic Stable Angina.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT02423265 Withdrawn - Clinical trials for Coronary Artery Disease

Efficacy of Ranolazine in Patients With Chronic Total Occlusions of Coronary Arteries

Start date: June 2015
Phase: Phase 4
Study type: Interventional

Anti-anginal drugs relieve ischemia and symptoms by reducing myocardial oxygen demand by reducing heart rate and or contractility (beta-blockers, phenylalkylamine and benzothiazepineate classes of calcium antagonists) or vasodilatation of the venous system (fall in pre-load) and coronary vessels. Late sodium channels remain open for longer in the presence of myocardial ischaemia. Ranolazine, a novel anti-anginal agent, acts by inhibiting the inward late inward sodium current (INaL), reducing intracellular sodium accumulation and consequently intracellular calcium overload via the sodium/calcium exchanger. It is currently thought that this reduction in intracellular calcium reduces diastolic myocardial stiffness and therefore compression of the small coronary vessels. There is considerable animal data to support this theory. There are good theoretical reasons to postulate that patients with chronically occluded vessels may derive less benefit from conventional anti-anginal agents, particularly vasodilators. The ischemic myocardium, subtended by the occluded vessel, will already be subject to significant concentrations of paracrine vasodilators such as adenosine. Ranolazine, therefore, may on the basis of its mechanism of action, provide greater relief of ischemia in such patients than conventional anti-anginal agents.

NCT ID: NCT00518921 Withdrawn - Clinical trials for Chronic Stable Angina

Capadenoson in Angina Pectoris

Start date: March 2008
Phase: Phase 2
Study type: Interventional

This is a multi-center and multi-national,randomized, double blind, placebo-controlled, 28-day treatment study with BAY 68-4986 taken orally or a matching placebo.